PDCD1 and neoplasm: Mechanistic studies revealed that CTLA-4 or PD-1/PD-L1 blockade significantly enhanced T cell receptor (TCR) signals in tumor-specific T cells which leads to stronger tumor-killing activity (32), the infiltration as well as the survival rate of T cells in tumor microenvironment (TME) were also enhanced accordingly (33, 34).